Letybo

Botulinum toxin type A, the active ingredient in Letybo, is a Botulinum toxin presented as an unknown strength/form for intramuscular use. It treats muscle hyperactivity disorders and is used in adult patients requiring temporary muscle relaxation.

GNH USA supplies Letybo as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Letybo is a botulinum toxin type A product that acts on neuromuscular transmission to reduce excessive muscle activity. It is indicated for several FDA‑ and EMA‑approved conditions: - Cervical dystonia: reduces abnormal neck muscle contractions and associated pain. - Blepharospasm: alleviates involuntary eyelid closure. - Upper‑limb spasticity: improves range of motion in post‑stroke or cerebral palsy patients. - Chronic migraine: decreases frequency of migraine days. - Primary axillary hyperhidrosis: limits excessive sweating. - Glabellar lines (cosmetic): smooths frown lines between the eyebrows.

Adverse reactions are generally related to the local pharmacologic action and the injection procedure.

Common Side Effects: - Injection site pain or discomfort. - Localized muscle weakness. - Bruising or hematoma at the injection site. - Headache. - Flu‑like symptoms. - Dry mouth.

Serious or Rare Side Effects: - Dysphagia or difficulty swallowing. - Respiratory compromise due to spread of toxin. - Generalized muscle weakness. - Allergic reactions including rash, itching, or anaphylaxis. - Vision changes such as double vision. - Urinary retention.

Before using Letybo, clinicians should consider patient‑specific factors and safety measures. - Contraindication: Known hypersensitivity to botulinum toxin or any formulation component. - Caution: Use in patients with neuromuscular disorders (e.g., myasthenia gravis) may increase risk of systemic effects. - Pregnancy: Safety not established; prescribe only if potential benefit justifies potential risk. - Breastfeeding: Limited data; weigh benefits against possible infant exposure. - Storage: Store at 2‑8 °C: keep refrigerated, protect from light, do not freeze or shake.

Botulinum toxin type A may interact with other agents that affect neuromuscular transmission.

Major Interactions (Avoid): - Aminoglycoside antibiotics (e.g., gentamicin): may potentiate neuromuscular blockade. - Curare‑type muscle relaxants: additive effect on muscle weakness. - Dantrolene: increased risk of severe weakness.

Moderate Interactions (Monitor Closely): - Anticholinergic drugs: may modify local effects. - Other botulinum toxin products: cumulative toxicity risk. - Calcium channel blockers: potential influence on muscle response. - General anesthetics that depress neuromuscular function: monitor peri‑operative muscle strength.